Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of Dividend is 26-Jun-2026.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs announced audited consolidated FY26 revenue of INR 27,629 million, up about 12% from INR 24,614 million last year, with profit after tax rising modestly to INR 5,098 million from INR 4,922 million. EPS (basic) for the year came in at INR 30.24 vs INR 29.24 (restated for bonus shares). The Board recommended a final dividend of INR 4 per share, taking total dividends for FY26 to INR 20.5 per share, with June 26, 2026 fixed as the record date. Separately, the company will acquire 100% of Shahbazkers Diagnostic Centre, set up a wholly owned subsidiary in Dubai (Dr. Lal PathLabs FZCO), and re-appoint Executive Chairman Dr. Arvind Lal and Independent Director Rajit Mehta for fresh five-year terms. Deloitte Haskins & Sells LLP issued an unmodified audit opinion, though it flagged an exceptional one-time charge of INR 301 million relating to the new Labour Codes.
Steady mid-teens revenue growth and an unchanged, healthy dividend payout should be viewed positively by shareholders, while the muted PAT growth and the one-time Labour Code charge slightly temper near-term earnings optics. The acquisition and Dubai expansion signal a continuing growth push, but meaningful benefits will depend on integration and execution.